title: [Clinical features of peripheral neuropathy in paraproteinemic hemoblastosis].
abstract: OBJECTIVE
  Peripheral neuropathy often occurs as a side effect of medication or as a manifestation of system disease. The purpose of this study was to evaluate the features of polyneuropathy with verified paraproteinemic hemoblastosis.
  
  
  METHODS
  We studied 104 patients, 72 women 32 men, aged 24-79 years. Along with neurological examination, authors studied vibration sensitivity and used electromyography and several scales for assessment of pain syndrome and other clinical presentations. RESULTS AND СONCLUSION: Clinical variants of peripheral neuropathy - neuropathy associated with paraproteinemia and neuropathy during treatment of advanced multiple myeloma with bortezomib (bortezomib-induced neuropathy), were singled out. An algorithm for the examination and treatment of patients with peripheral neuropathy was proposed.
authors.forename: A A
authors.initials: AA
authors.lastname: Yakovlev
authors.forename: M V
authors.initials: MV
authors.lastname: Yakovleva
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054219:Neoplasms, Plasma Cell / Q000150:complications / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000175:diagnosis*; D011115:Polyneuropathies / Q000150:complications / Q000175:diagnosis*; D011719:Pyrazines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib